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Abstract
Signal transducers and activators of transcription (STATs) are a family of 
cytokine-regulated transcription factors, which serve the dual role of external 
signal transduction and transcriptional activation. The founding member of this 
family, STAT1, is involved in a plethora of cellular processes, including interferon-
dependent upregulation of various effector mechanisms in immune and non-
immune cells to control bacterial, fungal and parasitic infections. In this chapter, 
we discuss the principles of STAT1-driven gene expression and focus on the clinical 
phenotypes of various human STAT1 mutations. In particular, we highlight the sig-
nificance of sequence-specific DNA binding and intact nucleocytoplasmic shuttling 
for full transcriptional activation of interferon-driven target genes.
Keywords: signal transducer and activator of transcription (STAT), Janus kinase 
(JAK), DNA binding, cytokine signalling, gene expression, interferon, gain-of-
function mutation
1. Introduction
The origins of the seminal discovery of the intracellular signal transmitters 
mediating cytokine signalling now date back nearly three decades. In the late 
1980s, a group of researchers observed that signal transmission could be induced 
within minutes after stimulating cells with type I interferons (IFNs). Such speed, 
with which the signal generated at the plasma membrane-bound receptor was 
transduced to the nucleus, suggested the presence of only a few intermediate steps. 
Eventually, the only two players involved were identified, which are receptor-
associated Janus kinases (JAKs) and the signal transducers and activators of 
transcription (STATs) [1]. The STAT proteins comprise a family of evolutionary 
highly conserved transcription factors, which are thought to have evolved with the 
development of the first multicellular organisms [2, 3]. They are expressed in vari-
ous metazoan animal species, including nematodes, insects and vertebrates [4–9]. 
In mammals, seven different STAT proteins have been identified, namely STAT1, 
STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6. The STATs are differentially 
activated by a variety of almost 50 extracellular signalling molecules, including 
interferons, interleukins, growth factors and hormones [10] and are involved in 
a plethora of biological processes, including cell differentiation, proliferation, 
development, immunity and apoptosis [11]. STAT1, the founding member of this 
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family, is the major signalling molecule activated by IFN-α/β and IFN-γ and plays a 
pivotal role in mediating immune responses to infectious pathogens. It is essential 
for the direct activation of various immune effector genes, including those cod-
ing for microbicidal molecules, antiviral proteins, antigen-presenting molecules, 
phagocytic receptors, chemokines and cytokines [12]. Not surprisingly, humans 
expressing STAT1 variants with nonsense or missense mutations often exhibit an 
increased susceptibility to bacterial and viral infections.
2. Design principles of the JAK/STAT signalling pathway
STAT signalling is a paradigm of a ligand-induced pathway from cell surface 
receptors to the transcriptional machinery, thereby connecting extracellular signals 
to the regulation of eukaryotic gene expression. The activation of STAT proteins and 
their mechanisms of action are unique in many ways: (i) This pathway represents 
one of the first examples of direct signalling to the nucleus without the involvement 
of second messengers, (ii) post-transcriptional modification by tyrosine phosphor-
ylation is a hallmark feature of this pathway and, (iii) STATs make direct contacts 
with both membrane-bound receptors and DNA, thereby integrating cellular 
processes at the membrane to nuclear events. The basic model of STAT signalling 
depends on a cascade of tyrosine phosphorylation steps, as shown in Figure 1 [11]. 
Binding of the ligand to its cognate cell surface receptor triggers the dimerization or 
multimerization of the transmembrane receptor subunits. Conformational changes 
in the receptor complex bring the non-covalently attached Janus kinases (JAKs) 
into close spatial proximity to each other and allow their trans-phosphorylation on 
specific tyrosine residues. As a result, the JAKs are activated and, in turn, phosphor-
ylate specific tyrosine residues on cytoplasmic receptor domains, thereby creating 
docking sites for latent, cytoplasmic STAT molecules which bind through their 
src-homology-2 (SH2) domain. All mammalian STAT proteins bear a conserved 
signature tyrosine residue near their C-terminus, which becomes phosphorylated 
by the JAKs. Upon this modification, they dissociate from the receptor complex and 
immediately dimerise via reciprocal phosphotyrosine (pY)-SH2 domain interac-
tions. With the exception of STAT2, all human STAT proteins form homodimers. 
In addition, STATs are frequently engaged in heterodimer formation, for example, 
STAT1:STAT2 and STAT1:STAT3, and the amount of heterodimeric STATs depends 
on the nature and concentration of the activating ligands.
Due to their large protein size (~180 kDa for the STAT1 dimer), nuclear import 
of activated STATs requires a carrier-facilitated transport process through the 
nuclear core complex. Nuclear trafficking of tyrosine-phosphorylated STAT is 
mediated by importin-α proteins [13]. Tyrosine-phosphorylated STAT1 dimers 
are translocated as cargo proteins by a mechanism depending on importin 
α-5:importin-β1 and the small G protein Ran [14–16], whereas nuclear import of 
STAT3, STAT5 and STAT6 appears to be mediated primarily by interaction with 
other members of the protein family of karyopherins [17, 18]. Once in the nucleus, 
the STAT proteins act as classical transcription factors and bind to specific regula-
tory DNA sequences to activate or repress the transcription of their target genes. 
All members of the STAT family bind to a palindromic consensus motif termed 
gamma-interferon activated sequence (GAS) (5′-TTCN3GAA-3′). A notable excep-
tion is STAT2, which appears to be defective in DNA binding and instead associates 
with STAT1 and interferon-regulatory factor 9 (IRF9) in a ternary complex, which 
is called interferon-stimulated gene factor 3 (ISGF3) [19]. This transcriptionally 
active complex binds to a distinct direct repeat motif (5′-AGTTTCN2TTTC-3′) 
termed interferon-α-stimulated response element (ISRE).
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The kinetics of STAT-mediated gene transcription is strictly regulated in both 
the cytoplasmic and nuclear compartment. The inactivation of nuclear STAT 
proteins rapidly occurs following nuclear import and initiation of gene transcrip-
tion. This process has been best studied for the founding member of this family, 
STAT1. When not contacting DNA, STAT1 dimers undergo a conformational 
change, which results in the exposure of the critical phosphotyrosine residue at 
position 701 [20–23]. In this conformation, STAT1 is highly susceptible to dephos-
phorylation by the nuclear isoform of the T-cell protein tyrosine phosphatase 
(Tc45) [24–26]. It has been demonstrated that Tc45 induced dephosphorylation is 
a prerequisite for STAT1 to exit the nucleus [27]. As shown for STAT1 and STAT3, 
nuclear export is assisted by the exportin CRM1 (chromosome region maintenance 
1), which acts in a Ran-dependent manner [28–32]. Back in the cytosol, STATs can 
then participate in additional cycles of cytoplasmic re-activation, nuclear import 
Figure 1. 
Model of the interferon-γ-induced JAK/STAT signal pathway depicting the activation-inactivation cycle of 
STAT1. Binding of IFN-γ to the cell surface receptor triggers JAK-induced tyrosine phosphorylation of STAT1 
(1). Through spontaneous dissociation and reassociation, the activated STAT1 molecules constantly oscillate 
between the parallel and antiparallel dimer conformation (2). Phosphorylated dimers are translocated to the 
nucleus via binding to importins (3) where they bind to gamma-interferon activated sequence (GAS) motifs, 
potentially polymerise and induce gene transcription (4). After a conformational shift (5), antiparallel dimers 
are susceptible to dephosphorylation by the nuclear phosphatase Tc45 (6) and thereafter exit the nucleus (7).
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and inactivation, depending on the activation status of the cytokine receptor at the 
plasma membrane [33].
The rapid onset of JAK/STAT signalling is followed by subsequent decay, which 
includes the inactivation of cytokine receptors and JAKs, leading to a decrease in 
transcriptional activity. Apart from inactivation by nuclear phosphatases, STAT-
mediated signal transduction is tightly controlled by additional negative regulators. 
A well-studied inhibitory mechanism involves the upregulation of proteins, collec-
tively termed suppressors of cytokine signalling (SOCS) [34, 35]. These inhibitory 
proteins are components of a classical autoregulatory feedback loop, since most 
SOCS protein-encoding genes are well-established STAT targets. The SOCS proteins 
are generally expressed at low levels in resting cells but become rapidly induced 
after key stimulus exposure. The SOCS protein family comprises SOCS1–7 and the 
cytokine-inducible SH2-domain-containing protein (CIS), which counteract the 
JAK/STAT signalling by distinct ways. For example, SOCS1 binds to the catalytic 
subunit of the receptor-associated JAKs [36], while SOCS3 binds additionally to the 
receptor [37]. Both processes result in the inhibition of JAK activity and prevent 
further STAT activation. In contrast, CIS and SOCS2 have been proposed to sup-
press STAT activation by directly competing with STATs for binding to receptor 
docking sites [38, 39]. Another antagonistic mechanism involves protein inhibitors 
of activated STAT (PIAS) [40]. The family members of PIAS proteins are thought 
to directly bind to activated STAT dimers and show specificity as well as redun-
dancy in their action: PIAS1, PIAS3 and PIASx bind to STAT1, STAT3 and STAT4, 
respectively [41–43], while PIASy interacts with STAT1 [44]. They employ distinct 
mechanisms to repress STAT-dependent gene transcription, for example, PIAS1 
and PIAS3 block the DNA-binding activity to prevent STATs from binding to their 
target promoters. In contrast, PIASx and PIASy act as transcriptional co-repressors 
by recruiting other co-repressors, including histone deacetylases (HDACs) to stop 
the initiation of transcription. Interestingly, unlike other general negative regula-
tors, PIAS1 does not counteract the entire STAT1-induced gene repertoire but rather 
selectively inhibits only a subgroup of genes [45].
3. Structure and conformations of dimeric STATs
Mammalian STATs are composed of 750–850 amino acids, and their molecular 
weights range between 80 and 113 kDa. Biochemical, genetic and structural studies 
have revealed that STAT family members share the same modular architecture with 
six conserved functional domains organised in three independently folded struc-
tural units (Figure 2). The characteristic domains are the amino-terminal domain 
(ND) involved in protein-protein interactions and the core fragment which is com-
posed of a coiled-coil domain (CCD), DNA-binding domain (DBD), linker domain 
(LD) and SH2 domain, followed by the carboxy-terminal transactivation domain 
(TAD) [46, 47]. The N-domain and the transactivation domain are connected 
to the core fragment through short flexible linkers, of which the C-terminally 
Figure 2. 
Domain structure of STATs. STAT proteins are composed of conserved functional domains: ND: amino-
terminal domain, CCD: coiled-coil domain, DBD: DNA-binding domain, LD: linker domain, SH2: 
src-homology-2 domain, TS: phosphotyrosyl tail segment with the specific phosphorylation site, TAD: 
transactivation domain.
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located one harbours the conserved tyrosine residue in a stretch referred to as the 
phosphotyrosyl tail segment (TS). The overall similar structure and high conserva-
tion among the STAT proteins reflect similarities in activation, dimerization and 
DNA binding. The two most conserved structures are the N-domain and the SH2 
domain, both of which facilitate protein interactions, for example, dimerization 
[48], binding of the transcriptional co-activator CBP/p300 [49] or binding to the 
receptor. The transactivation domain is intrinsically unstructured and undergoes 
folding transition upon interaction with transcriptional co-activators [50]. Its 
residues vary considerably among the STAT family members affording divergent 
ways to activate individual target genes.
The first crystallographic analyses of STAT proteins revealed the structure of 
the core fragments of phosphorylated STAT1 and STAT3 lacking the N-domain 
and parts of the transactivation domain [46, 51] (Figure 3A–C). Details of the 
STAT-DNA interaction showed substantial similarities among the various members 
of the STAT protein family. The crystal structures of unphosphorylated STAT1 
(Figure 3D–F) and STAT5A dimers, as well as N-domain dimers of STAT4, greatly 
extended our general knowledge about the STAT proteins [48, 52, 53]. The original 
concept of latent STATs existing as cytoplasmic monomers [54] was soon chal-
lenged by a growing body of compelling evidence arguing for dimeric conforma-
tion prior to stimulus exposure. Crystallographic analyses of STAT1 and STAT5A 
Figure 3. 
Localisation of selected gain-of-function mutations within the STAT1 dimer. (A–C): Crystal structure of 
dimeric STAT1 in parallel conformation bound to DNA including the positions of some important site chains 
which, when mutated, cause an inborn error. The images show a ribbon diagram (A, B, D, E) or a molecular 
surface structure (C, F) of a STAT1 core fragment in parallel (A–C) and antiparallel dimer conformation 
(D–F), respectively. The enlarged section of the ribbon diagram demonstrates the spatial orientation of the 
residues F172 and T385 (coloured in magenta) in the interdimeric CCD:DBD interface. The selected GOF 
mutation sites F172, R274, F364 and T385 are marked in magenta. The STAT1 domains are coloured according 
to the panel in Figure 2. CCD: coiled-coil domain. DBD: DNA-binding domain. LD: linker domain. SH2: 
src-homology-2 domain.
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revealed unphosphorylated protomers self-assembled in a head-to tail alignment 
where the SH2 domains project from opposite ends of the dimer (Figure 3D–F). In 
this antiparallel conformation, the extended dimeric interface is formed by recipro-
cal interactions between the coiled-coil domain of one protomer and the DNA-
binding domain of its partner protomer (CCD:DBD) [52, 53].
Despite significant efforts, it is still unclear whether a stable dimerization of 
unphosphorylated monomers is common to all STATs. In addition to unphosphory-
lated homodimers, experimental data indicate the existence of STAT1:STAT2 and 
STAT1:STAT3 heterodimers prior to cytokine stimulation [55, 56]. In contrast to the 
antiparallel alignment in the absence of stimulation, activation of the JAK/STAT 
signal pathway results in the formation of dimers in parallel conformation, where 
the tyrosine-phosphorylated protomers arrange themselves in a highly symmetric 
head-to-head alignment held together by reciprocal phosphotyrosine (pY)-SH2 
domain interactions [46, 51] (Figure 3A–C). In this conformation, homotypic 
STAT dimers bind to DNA without the need of further protein-protein interac-
tions between the two protomers. It has been shown that tyrosine-phosphorylated 
STAT1 must first become dephosphorylated by nuclear phosphatases to be capable 
of leaving the nucleus to participate in additional rounds of a cytosolic reactivation 
and nuclear deactivation [27]. In the parallel conformation, the two phosphorylated 
tyrosine residues are buried in the opposing SH2 domain pockets, thereby protect-
ing STAT1 from being dephosphorylated. By the conformational rearrangement of 
the STAT1 dimer from a parallel to an antiparallel alignment, the critical phospho-
tyrosine residues are subjected to enzymatic dephosphorylation [23].
The molecular details of the transition between the parallel and antiparallel STAT1 
dimer conformation are still controversial. Initially, a model was proposed in which 
the N-terminal domains dimerise and keep the dimer partners held together, while 
the monomer’s core domains rotate around each other after phosphotyrosine-SH2 
disjunction [22]. The alternative mechanism, widely accepted today, describes the 
conformational reorientation as achieved by spontaneous dissociation of the tyrosine-
phosphorylated dimer into isolated monomers and their reassociation in antiparallel 
alignment [20, 57]. Studies indicate that STAT1 constantly oscillates between the two 
dimer conformations, and the abundance of each conformer is determined by the 
level of tyrosine phosphorylation. While unphosphorylated molecules exist in mono-
meric or dimeric, antiparallel conformation, there is a conformational equilibrium 
between phosphorylated dimers in parallel and antiparallel alignment [20].
4. Nucleocytoplasmic shuttling and transcriptional activity
Initially, STAT proteins were considered to function as latent transcription fac-
tors, which translocate to the nucleus and induce gene transcription exclusively in 
response to stimulus exposure. However, STAT1 and STAT3 were found to be present 
in the nucleus independent of tyrosine phosphorylation [33, 58, 59]. It became 
evident that, in contrast to phosphorylated STATs that are actively transported into 
the nucleus, the nuclear import of unphosphorylated STATs is facilitated by direct 
interactions with protein components constituting the nuclear pore complex [28]. 
This carrier-free translocation follows the concentration gradient across the nuclear 
envelope and, as facilitated diffusion, does not depend on metabolic energy. Thus, 
STAT proteins are constantly shuttling between the cytoplasmic and nuclear com-
partment, irrespective of their activation status. For some STAT family members, 
for example, STAT1, STAT2, STAT3 and STAT6, it has been shown that they play 
important roles in facilitating gene expression in the absence of stimuli and tyrosine 
phosphorylation [60–64]. In principle, unphosphorylated STAT1 is able to bind to 
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DNA, but its binding activity is 200-fold lower than that of activated STAT1 and, 
therefore, may not have any physiological relevance as a DNA-binding protein with-
out the recruitment of cofactors [20]. In line, unphosphorylated STAT1 was found in 
a complex with interferon-regulatory factor 1 (IRF1) to bind DNA at the promoter of 
the low molecular mass polypeptide 2 (LMP2) gene, which contains overlapping bind-
ing sites for both transcription factors [65]. The LMP2 gene encodes a component of 
the 20S proteasome and is induced by stimulation of cells with IFN-γ, but it is also 
expressed at low levels in the absence of cytokines [66]. From these experiments, it 
became clear that unphosphorylated STAT1 functions as a transcription factor, since 
it is directly responsible for constitutive LMP2 expression, but it is rapidly replaced 
by activated STAT1 dimers in response to IFN-γ stimulation [65].
More recently, it was reported that, in comparison to STAT1-deficient knockout 
animals, the pathogene Listeria monocytogenes grows less robustly in knockin mice 
expressing the Y701F mutant, which is unable to be tyrosine phosphorylated, indi-
cating a potential contribution of unphosphorylated STAT1 to innate antibacterial 
immunity [67]. Due to a positive autoregulatory loop of STAT1 signalling, expression 
of unphosphorylated STAT1 molecules is greatly increased after activation of STAT1. 
While the phosphorylation in response to IFNs lasts only for several hours, newly syn-
thesised unphosphorylated STAT1 persists for several days and results in enhanced 
signal transduction when the cells are thereafter re-exposed to low doses of IFN [68].
5. Serine phosphorylation and its effect on transcriptional activity
Apart from canonical, tyrosine phosphorylation STAT-driven transcription is also 
regulated by a number of posttranslational modifications, including serine phosphor-
ylation and sumoylation. All STATs except STAT2 can become phosphorylated at least 
at one serine residue embedded in a proline-rich sequence in the C-terminal transac-
tivation domain [69]. An evolutionary conserved phosphorylation site includes Ser 
727 in STAT1 and STAT3, Ser 721 in STAT4, Ser 725 in STAT5A, Ser 730 in STAT5B and 
Ser 756 in STAT6 [70, 71]. The maximal transcriptional activity and biological effects 
of at least STAT1, STAT3, and STAT4, and possibly also STAT5A, require both tyrosine 
and serine phosphorylation [70, 72–75]. This was corroborated by infection experi-
ments with mice unable to become phosphorylated at STAT1 Ser 727. Mice expressing 
STAT1 S727A died when challenged with high doses of the intracellular pathogen 
Listeria monocytogenes, whereas 80% of the wild-type littermates survived [72]. In the 
case of STAT1, a variety of signals cause the phosphorylation of Ser 727 and multiple 
candidate serine/threonine kinases have been implicated in this process. For example, 
interferons induce serine phosphorylation in addition to prior tyrosine phosphoryla-
tion. It was reported that, for canonical serine phosphorylation, STAT1 needs to be 
assembled into chromatin-bound transcriptional complexes and that the responsible 
kinase itself is similarly associated with DNA [76]. In this light, it was proposed that 
STAT1 recruits the cyclin-dependent kinase 8 (CDK8) to IFN-γ-driven target genes, 
which provides the kinase activity [77].
The need for serine phosphorylation to enhance transcriptional activity of 
STAT1 varies with different target genes and cell types, suggesting a complexity, 
which is not yet fully understood [72, 78]. It is hypothesised that STAT1 serine 
phosphorylation provides an extra supply of IFN-γ-induced gene products that are 
critical for full protection against pathogens [72]. Signals such as bacterial lipo-
polysaccharide (LPS) or mediators of inflammation and cellular stress exclusively 
stimulate the phosphorylation of serine 727, independent of tyrosine phosphoryla-
tion [79]. This modification takes place in the cytosol and involves the p38 mitogen-
activated protein kinase (MAPK) pathway [80, 81]. It has been proposed that the 
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biological relevance of serine phosphorylation is to prime STAT1 for an increased 
transcriptional response once IFN-γ provides the stimulus for tyrosine phosphory-
lation [78], as observed for macrophage activation.
An important paper from the Vinkemeier lab demonstrated that the activity of 
STAT1 is inhibited by conjugation to small ubiquitin-like modifier (SUMO), which 
is added to Lys 703 [82]. Although only a small fraction of the intracellular, unphos-
phorylated STAT1 pool is sumoylated, the modification by SUMO interferes with 
the formation of paracrystalline arrays in the nucleus, which sequester activated 
STAT1 molecules. SUMO conjugation diminishes the activity of STAT1 by interfer-
ence with tyrosine phosphorylation and, in addition, solubilizes the highly dynamic 
paracrystals in cytokine-stimulated cells [83].
6. Mechanisms of STAT1 DNA binding
Sequence-specific DNA binding of STAT proteins is a prerequisite for their 
function as cytokine-driven transcriptional regulators. STATs interact with high-
affinity binding sites on DNA through their DNA-binding domain, which shows the 
general architecture of an immunoglobulin fold [46, 47]. The crystal structure of 
DNA-bound STAT1 revealed that the transcription factor engages in several inter-
actions with the phosphodiester backbone of the DNA, but makes relatively few 
base-specific contacts, for example, through the residues Asp 460 and Lys 336 in 
the major and through Glu 421 in the minor groove [46]. Each STAT protomer binds 
to a half-site of a palindromic consensus motif termed gamma-interferon activated 
sequence (GAS). STAT1, STAT3, STAT4 and STAT5 bind to half-sites spacing two or 
three base pairs (5′-TTCN2-3GAA-′3), while STAT6 favours a four nucleotide spacer 
within the palindrome [84, 85]. The nucleotides between and around the core 
palindrome impart some level of specificity.
The implication of impaired DNA-binding activity became evident, when STAT1 
mutants were engineered by substituting numerous residues within the DNA-binding 
domain that potentially make contacts with the phosphodiester backbone of the 
DNA. The introduction of positive, negative or neutral charges was intended to 
increase or reduce electrostatic interactions between STAT1 and DNA, respectively. 
A STAT1 mutant termed STAT1 DNAminus, in which negative charges were introduced 
by substituting aspartic acid (Asp) for valine (Val) at position 426 (Val426Asp) and 
threonine at position 427 (Thr427Asp), was normally tyrosine phosphorylated in 
response to IFN-γ but essentially lost its DNA-binding activity [27]. The STAT1 
DNAminus mutant was highly susceptible to inactivation by the nuclear phosphatase 
Tc45 and failed to accumulate in the nucleus. In contrast, the mutant STAT1 DNAplus 
(Thr327Arg; Val426His; Thr427His) was capable of strongly binding to both specific GAS 
sites and nonspecific DNA sequences with nearly equal affinity. This mutant lost its 
discrimination for GAS sites and, due to its hindered dissociation from DNA, resisted 
dephosphorylation, resulting in prolonged nuclear accumulation [27]. These and 
additional experiments indicated that DNA binding determines the accumulation of 
STAT1 in the nucleus. This assumption was corroborated by the finding that high-
affinity DNA binding reduces the dissociation rate of STAT1 dimers from DNA and 
impairs the interdimeric exchange of their protomers in the presence of DNA [57].
In contrast to STAT1 DNAplus, substitution of two glutamic acid residues 
(Glu411Ala; Glu421Lys) generates a double mutant, which maintains the discrimina-
tion between GAS and nonspecific sites. However, STAT1-DNA complexes are stabi-
lised independent of the nucleotide sequence, leading to persistent and enhanced 
tyrosine phosphorylation and prolonged nuclear accumulation [86]. The presence 
of negatively charged residues at these positions is critical for the release of STAT1 
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from DNA. IFN-γ-induced expression of reporter genes and endogenous target 
genes is dramatically reduced in cells expressing STAT1 DNAplus, STAT1 Glu411Ala 
or STAT1 Glu421Lys [27, 86]. In summary, these data revealed the significance 
of sequence-specific DNA binding and fast dissociation from DNA for efficient 
STAT1-mediated gene regulation. An impaired dissociation of STAT1 from genomic 
DNA not only interferes with the continuous search for GAS sites but also prevents 
fast nucleocytoplasmic shuttling and full transcriptional activity of STAT1.
Early studies on the DNA binding of STATs revealed that their binding sites 
can extend over two or more adjacent consensus motifs and that activated STAT1, 
STAT3, STAT4 and STAT5 dimers can interact in homotypic fashion to polymerise on 
such DNA sequences, that is form tetramers or even higher order oligomers [48, 87–
91]. GAS motifs linked in tandem orientation have been identified in various STAT-
driven target genes, including, for example, those encoding IFN-γ [90], interleukin 
2 receptor α (IL-2Rα) [87, 88], perforin [92], cytokine-inducible SH2-containing 
protein (CIS) [93], α2-macroglobulin (α2-M) [91], and glycosylation-dependent cell 
adhesion molecule 1 (GlyCam1) [94]. The synergistic recognition of DNA, generally 
referred to as cooperative DNA binding, is mediated by the conserved N-terminal 
domain of the STAT proteins. It was shown that deletion or mutation of the STAT 
N-terminus abolishes cooperative dimer-dimer interactions [48, 89–91, 95].
Analysis of the crystal structure of the N-domain dimer has indicated an exten-
sive interface involving interactions between hydrophobic residues [96]. Targeted 
mutagenesis has revealed an orthologue residue (Phe 77 in STAT1 and Phe 81 in 
STAT5A/B, respectively) as physiologically most relevant for the oligomerisation 
of STAT proteins [95, 96]. Substitution of alanine for the critical phenylalanine in 
STAT1 does not overtly affect DNA binding on a single GAS site in response to IFN-γ 
but severely impairs tetramerisation [95, 97]. The cooperative binding of STAT1 
dimers strongly increases their DNA-binding affinity [89]. Such interactions do not 
require high-affinity GAS sites linked in tandem orientation. In vitro studies have 
revealed the recruitment of multiple STAT1 dimers to a single GAS site adjacent to 
low-affinity or even GAS-unrelated sequences [95]. Thus, N-domain interactions 
of DNA-bound STAT1 molecules greatly expand the repertoire of potential STAT1-
regulated IFN-γ target genes. An in silico analysis revealed that although single GAS 
sites frequently occur in the mouse genome, GAS sites linked in tandem orienta-
tion are rare and may not be enriched in IFN-γ target genes [97]. Paradoxically, a 
genome-wide transcriptional analysis revealed that STAT1-mediated cooperative 
DNA binding is indispensable for IFN-γ signalling, since the IFN-γ response is 
essentially lost in murine cells expressing the STAT1 F77A mutant [97]. Furthermore, 
cooperativity-deficient STAT1 F77A showed a pervasive promoter recruitment defect 
at GAS-containing IFN-γ-driven but not IFN-α/β-driven genes. It has, therefore, 
been proposed that STAT1 tetramerisation or polymerisation originates from a GAS 
site and then proceeds with loose additional requirements for adjacent sequences 
[97]. Infection experiments have highlighted the physiological relevance of STAT1 
tetramerisation. Listeria monocytogenes infection of STAT1 F77A-expressing mice 
revealed a severe defect in antibacterial immunity. The STAT1 cooperativity-defi-
cient animals succumbed more easily than their wild-type littermates [97].
The crystal structure of the unphosphorylated STAT1 dimer indicates that the 
dimerisation interface is composed of the phenylalanine residue 172 in the coiled-
coil domain of one protomer, which reciprocally is inserted into a pocket in the 
DNA-binding domain of its partner molecule. This pocket is created by the residues 
Q340, L383, G384, T385, H406, L407 and Q408 [52]. Several GOF mutations have 
been identified at this interdimeric interface [98, 99]. Studies on the molecular 
basis of these point mutations underscore the paramount importance of the con-
formational shift for STAT1-driven gene expression [98]. The critical phenylalanine 
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residue 172 is in close proximity (7 Å) to the threonine residue 385 at the surface of 
the partner protomer (Figure 3E). Its substitution impedes the reciprocal interac-
tions between the coiled-coil and DNA-binding domain of the two interacting 
STAT1 molecules, thereby negatively affecting the stability of the antiparallel 
dimer conformation. Shifting the conformational equilibrium towards the parallel 
conformation buries the critical tyrosine residue 701 inside the SH2 domain and, 
thus, prevents access for nuclear phosphatases.
Another interesting phenotype was reported from the targeted mutagenesis of 
the phenylalanine residue 364. The crystal structure indicates that this residue locates 
in the centre of the DNA-binding domain and contributes to the gross structural 
alignment of this domain (Figure 3). The F364A mutant is characterised by tyrosine 
hyper-phosphorylation in response to stimulation of cells with IFN-γ, most likely 
because of its hampered interaction with the Tc45 phosphatase and, in addition, a 
significantly reduced DNA-binding activity. The data suggest that Phe 364 is crucial 
for stabilising the antiparallel dimer and, in addition, for recognising DNA-binding 
sites. When assessed for its ability to induce endogenous STAT1-regulated genes, the 
mutant unexpectedly shows a well-preserved transcriptional activity. Remarkably, it 
appears that a shift in the equilibrium towards the parallel dimer conformation can 
compensate for a critical impairment in high-affinity DNA binding, restoring nearly 
full transcriptional activity at IFN-γ-induced target genes [21].
7. Phenotypes of patients with inborn errors of human STAT1
Regulation of the JAK-STAT signalling pathway is most critical, and dysfunc-
tions in this pathway are associated with various immune disorders and cancer. 
Either the loss of STAT transcriptional activity or uncontrolled constitutive, 
prolonged activity can have devastating effects. Recent progress in the genetic 
dissection of various human infectious diseases has shed light on the inborn errors 
of human STAT1-mediated immunity. In the latest version of the publicly accessible 
section of the Human Gene Mutation Database (HGMD), more than 40 missense/
nonsense mutations in the Stat1 gene have been listed as disease-causing muta-
tions. These include mutations with (i) autosomal recessive (AR) complete STAT1 
deficiency, (ii) AR partial STAT1 deficiency, (iii) autosomal dominant (AD) STAT1 
deficiency and (iv) AD gain-of-function activity. Biallelic and even monoallelic 
loss-of-function (LOF) mutations have been associated with lethal or milder patho-
genesis of intramacrophagic bacterial and viral diseases. In addition, STAT1 LOF 
mutations have been identified in the rare syndrome of Mendelian susceptibility to 
mycobacterial disease (MSMD), which is characterised by infections with weakly 
virulent mycobacteria in otherwise healthy individuals. Patients with immunologi-
cal defects caused by gain-of-function (GOF) mutations suffer from autoimmunity 
and recurrent or persistent infections of nails, skin and mucous membranes with 
the opportunistic yeast pathogen Candida albicans, referred to as chronic mucocu-
taneous candidiasis (CMC) [100–102] (Table 1).
Studying the structural and functional impact of STAT1 missense mutations 
has greatly contributed to our current understanding of cytokine-regulated 
transcriptional activity. To decipher the underlying molecular mechanisms of the 
known STAT1-mediated immunodeficiencies, the pathogenic amino-acid substitu-
tions need to be assigned to the structural changes they induce in the context of 
intra- and intermolecular interactions [112]. When mapped to the crystal structure, 
it becomes evident that the occurrence of disease-causing mutations is unevenly 
distributed among the different STAT1 domains. It appears that the preferential 
11
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Figure 4. 
Phenotype of clinically relevant STAT1 GOF mutations. (A, B): Characterisation of the STAT1 mutation 
T385A. (A) Localisation of fusion proteins of green-fluorescent protein-tagged STAT1 in reconstituted 
U3A cells expressing recombinant wild-type STAT1 or STAT1 T385A. Exposure to the kinase inhibitor 
staurosporine resulted in the loss of IFN-γ-induced nuclear accumulation of wild-type STAT1, whereas, in 
contrast, the STAT1 point mutant showed a significantly prolonged nuclear residence. (B) Impaired tyrosine 
dephosphorylation of the GOF mutant, as shown by Western blotting. Incubation of protein extracts from 
STAT1-reconstituted U3A cells with the STAT1-specific nuclear phosphatase TC-PTP (Tc45) led to rapid 
dephosphorylation of wild-type STAT1, while the level of tyrosine phosphorylation was prolonged in the T385A 
mutant. (C) Intraoral chronic mucocutaneous candidiasis in a patient carrying the heterozygous STAT1 GOF 
mutation R274Q.
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localisation of LOF mutations is less well defined as compared to the more restricted 
localisation of GOF mutations. The critical LOF substitutions are widely scattered 
in the coiled-coil, DNA-binding and SH2 domains, as well as in the tail segment. In 
contrast, the GOF mutations identified so far are exclusively clustered in the coiled-
coil and DNA-binding domains. The crystal structure of tyrosine-phosphorylated, 
DNA-bound STAT1 shows that the coiled-coil domain prominently protrudes 
outward [46]. Therefore, it was initially postulated that the coiled-coil domain may 
function as a docking site for transcription factors and coactivators to cooperatively 
facilitate STAT1-dependent gene transcription and that the GOF mutations in this 
domain may enhance these interactions. Typically, pathogenic GOF mutations clus-
ter in structural areas of the STAT1 protein, which markedly affect the regulation of 
its transcriptional activity. As described above, the conformational rearrangement 
from the parallel to the antiparallel dimer conformation is a prerequisite for the 
inactivation of STAT1 and requires, as a conditio sine qua non, the dissociation into 
monomers. Monomeric STAT1 spontaneously reassociates into either the parallel 
or antiparallel conformation. In the parallel alignment, STAT1 regains its DNA-
binding activity with the chance of participating in another round of transcrip-
tional initiation of target genes. It appears that the antiparallel conformation of the 
STAT1 dimer is the substrate for the highly active Tc45 phosphatase, which rapidly 
dephosphorylates the critical tyrosine residue 701 followed by nuclear export of the 
now transcriptionally inactive molecule. As described above, the formation of the 
antiparallel dimer is facilitated by reciprocal interactions between the coiled-coil 
and the DNA-binding domain and, thus, it is not surprising that mutations in this 
critical area affect the stability of this complex.
Experimental data revealed that the two point mutants STAT1 F172W and T385A 
are resistant against dephosphorylation by the Tc45 phosphatase, which results in 
Domain/
region 
affected
Main cellular 
phenotype
Predominant clinical 
phenotype
References 
(incomplete)
AR complete 
STAT1 
deficiency
ND, SH2 No STAT1-
dependent response 
to IFN-α/β, IFN-γ, 
IFN-λ, IL-27
Life-threatening 
intracellular bacterial 
(mostly mycobacteria) 
and viral (mostly 
herpes) diseases
[103–105]
AR partial 
STAT1 
deficiency
ND, CCD, TS Impaired STAT1-
dependent response 
to IFN-α/β, IFN-γ, 
IFN-λ, IL-27
Mild intracellular 
bacterial (mostly 
mycobacteria) and viral 
(mostly herpes) diseases
[106, 107]
AD LOF 
STAT1 
disorder
CCD, DBD, 
SH2, TS
Impaired STAT1-
dependent response 
to IFN-γ, IL-27
Mendelian susceptibility 
to mycobacterial disease 
(MSMD)
[108, 109, 
116]
AD GOF 
STAT1 
disorder
CCD, DBD Enhanced STAT1-
dependent response 
to IFN-α/β, IFN-γ, 
IFN-λ, IL-27, IL-6, 
IL-21, impaired 
IL-17-mediated 
T-cell immunity
Chronic mucocutaneous 
candidiasis (CMC)
Autoimmunity
[99, 110, 111]
AD, autosomal dominant; AR, autosomal recessive; CCD, coiled-coil domain; DBD, DNA-binding domain; GOF, 
gain-of-function; LOF, loss-of-function; ND, amino-terminal domain; SH2, src-homology-2 domain; TS, tail 
segment.
Table 1. 
Inborn errors of human STAT1-mediated immunity.
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prolonged nuclear accumulation in cells exposed to IFN-γ (Figure 4A, B) [113]. 
The resulting phenotype is associated with enhanced tyrosine phosphorylation in 
response to various cytokine stimuli, including IFN-α, IFN-γ, IL-6, IL-21 and IL-27 
[23, 110, 113–115]. The functional characterisation of the disease-causing interface 
mutations has demonstrated sequence-specific requirements for differential gene 
expression of endogenous IFN-γ target genes. The expression of genes with a clas-
sical GAS consensus-binding motif, including interferon-regulatory factor 1 (irf1), 
guanylate-binding protein 1 (gbp1) and monokine induced by interferon gamma 1  
(mig1), is virtually unaffected by these mutations. In contrast, transcription of 
genes, such as CXC motif chemokine 10 (cxcl10) and monocyte chemotactic protein 1 
(mcp1/cxcl9) is greatly increased, which have a “one-and-a-half-GAS” element in 
their promoters, that is, half of the palindromic motif adjacent to the GAS site 
[113]. The superiority of the STAT1 mutants as transcriptional activators appears 
to directly reflect their enhanced binding as tetramers to these “one-and-a-half-
GAS” sequences. The increased DNA binding for these mutants contributes to 
their pathologically elevated level of tyrosine phosphorylation. However, numer-
ous disease-associated GOF mutations are not directly located at the surface of the 
interdimeric interface but rather disturb the gross architecture of this interface 
(Figure 3).
A prominent and well-studied example is the GOF mutation resulting from the 
exchange of the arginine 274 residue in the coiled-coil domain (Figure 4C). A change 
in the local structure induced by this substitution may impair the stability of the 
antiparallel dimer. Consistently, a genome-wide expression profile indicated that the 
pathogenic R274Q mutation increased the IFN-γ-induced transcriptional activity of 
STAT1 but overall retained its sequence specificity [98]. In other words, the mutation 
increases the expression rate of STAT1 target genes but does not dramatically change 
its repertoire. However, the molecular mechanisms of this GOF mutation are not fully 
understood. In particular, it is unclear whether this missense mutation affects the 
kinetics of JAK-induced phosphorylation or, alternatively, its dephosphorylation rate.
8. Concluding remarks
Activation at the IFN receptor and sequence-specific, cooperative DNA binding 
are key features of STAT1 signal transduction. Cytoplasmic and nuclear activities 
are functionally coupled by repetitive cycles of STAT1 phosphorylation and dephos-
phorylation. This highly dynamic activation-inactivation circuit is controlled by a 
shift between the parallel and antiparallel dimer conformers. Missense mutations in 
either the coiled-coil or DNA-binding domain destabilising the antiparallel dimer 
critically interfere with the equilibrium between the two conformers. Genetic varia-
tions affecting this intradimeric interface result in enhanced cytokine-induced gene 
expression and cause severe immunodeficiencies in heterozygous mutation carriers.
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